Single-arm phase II study of aggressive local therapy in combination with systemic chemotherapy for stageIV non-small cell carcinoma not harboring EGFR mutation and ALK fusion gene with oligometastases

Single-arm phase II study of aggressive local therapy in combination with systemic chemotherapy for stageIV non-small cell carcinoma not harboring EGFR mutation and ALK fusion gene with oligometastases - CURE-OLIGO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022431

Enrollment

Registered

2016-06-01

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Interventions

Platinum doublet + thoracic radio therapy Surgery for oligometastases Radiotherapy for oligometastases

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Aged 20-74 and Informed consent 2)ECOG PS 0-1 3)Stage IV non-small cell lung cancer 4)EGFR wild type and ALK negative or not detected 5)Only one metastasis legion (pleural effusion, cardiac effusion, pleural dissemination, peritoneal dissemination, and/or ascites are ineligible). However, resectable brain metastasis or brain metastasis that have adaptation of the gamma knife are allowed to four. 6)Curable concurrent chemoradiotherapy are available. 7)At least 8 weeks from local treatment completion for metastasis or no treatment.

Exclusion criteria

Exclusion criteria: 1) Patients with pleural effusion, cardiac effusion, pleural dissemination, peritoneal dissemination, and/or ascites 2) Patients who are ineligible to treat with thoracic radiotherapy due to interstitial pneumonitis and/or severe COPD

Design outcomes

Primary

Measure	Time frame
Two-year survival rate	—

Secondary

Measure	Time frame
-Overall Survival -Progression Free Survival -Adverse Event	—

Countries

Japan

Contacts

Public ContactTakaaki Tokitou

Kurume University School of Medicine Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine

kitou_takaaki@kurume-u.ac.jp0942-31-7560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026